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Abstract
Background: Distinction between non-neoplastic and neoplastic bladder lesions is therapeutically
and prognostically important. Our objective is to describe the use of double immunohistochemistry
(DIHC) for p53+CK20 as a tool for diagnosing neoplasia in bladder biopsies.
Methods: p53+CK20 DIHC were examined in 38 reactive atypia, 10 dysplasia, 9 carcinoma in situ
(CIS) and 7 invasive carcinoma (IC) cases. CK20 was evaluated according to distribution extent and
degree of intensity whereas percentage of positive cells together with staining intensity was taken
into account in the evaluation of p53.
Results: 92% of reactive cases were either CK20(-) or (+) only in the upper 1/3 urothelium. In
dysplastic cases CK20 staining distribution was as follows: 60% in 2/3 of the urothelium, 30% full
thickness, 10% in the upper 1/3 urothelium. Among CIS cases, 89% had full thickness CK20
positivity, of which 62% were p53(+). 71% of IC cases exhibited strong and full thickness dual
staining.
Conclusion: This is the first study in the literature to use DIHC of p53+CK20 in distinction of
non-neoplastic and neoplastic bladder lesions. Dual staining by p53+CK20 cocktail allows for
histologic correlation and diminishes the risk of losing the area of interest in limited biopsy
specimens.
Background
Urothelial carcinoma is the 7th most common cancer
worldwide with 260,000 new cases in men and 76,000
cases in women per year [1]. Furthermore, it is the 4th lead-
ing cause of cancer in American men with 14,100 deaths
per year in the US [2].
2004 World Health Organization/International Society of
Urological Pathology (WHO/ISUP) consensus committee
classifies flat urothelial lesions with atypia as reactive
urothelial atypia (RUA), atypia of unknown significance
(AUS), urothelial dysplasia (UD) and carcinoma in situ
(CIS) [1,3]. UD is defined by "appreciable loss of polarity
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with nuclear rounding and crowding and cytologic atypia
that is not severe enough to merit a diagnosis of CIS."
whereas AUS is a descriptive category for cases in which
dysplasia cannot be ruled out for sure, because of a degree
of atypia that is discordant with the extent of inflamma-
tion [1]. Both UD and CIS are precursor lesions of invasive
carcinoma and their presence is associated with a high risk
of progression and recurrence [3-5]. Although the mor-
phologic criteria is very useful, CIS diagnosis may be chal-
lenging in cases where the reactive/therapy atypia is in the
differential diagnosis. Generally, in reactive atypia, polar-
ity is maintained and accompanying inflammation or his-
tory of reactive conditions (calculi, trauma,
instrumentation or infection) may be present and cells
lack irregular chromatin distribution and pleomorphism.
The presence of large, irregular, hyperchromatic nuclei,
large nucleoli, and frequent mitoses including atypical
ones in the midurothelium to upper urothelium raise the
possibility of CIS [1]. However, some patterns of CIS lack
pleomorphism and may mimic reactive atypia [6]. CIS
cases with scattered atypical cells and pagetoid spread may
be underdiagnosed because of the absence of full-thick-
ness atypia and may be overlooked as non-neoplastic
lesions [7].
Persistent UD or CIS in a background of therapy is consid-
ered as therapy failure and may lead to radical cystectomy.
Therefore differentiating UD and CIS from RUA in the
background of inflammatory/post-therapy changes is crit-
ical because of appearent therapeutic and prognostic
implications. Other reasons such as small specimen size
and interobserver differences may also contribute to diffi-
culties in making the correct diagnosis [7]. Morphology
alone may not be sufficient in the differentiation. Hence,
in diagnostically difficult cases of AUS, specific markers of
UD and CIS to enhance morphology would be of great
utility to pathologists in distinguishing RUA from UD and
CIS.
In the search for reliable markers; p53 and cytokeratin 20
(CK20) are emerging as useful indicators of neoplastic
change and prognosis in urothelial proliferations as the
reports in favor of them accumulate [8-12].
Methods
64 bladder biopsies, consisting of 38 benign/reactive, 10
dysplasia, 9 CIS, and 7 invasive carcinoma (IC) (6 papil-
lary, 1 flat) cases, were retrieved from our surgical pathol-
ogy files. The samples were fixed in 10% buffered
formalin solution and embedded in paraffin blocks. The
biopsies were diagnosed according to the 2004 WHO clas-
sification of tumors of the urinary system [1].
Sections (4 μm) from each case were obtained. Deparaffi-
nization, rehydration, and antigen unmasking were
achieved by boiling sections in a commercially available
steamer. After quenching endogenous peroxidase, slides
were incubated with a cocktail of p53+CK20 composed of
10 ul of anti-p53 polyclonal antibody (1:500; DAKO,
Carpinteria, CA), 50 ul of anti-CK20 monoclonal anti-
body (1:100; DAKO, Carpinteria, CA) and 4,940 ul of Van
Gogh Yellow diluent. The detection system used was a
double stain polymer detection kit.
H&E and double immunohistochemistry (DIHC) of
p53+CK20 were examined for each case. Nuclear staining
for p53 and cytoplasmic staining for CK20 were inter-
preted as positive. p53 was evaluated according to the
ratio derived from the number of p53-positive cells and
staining intensity and scored as: 0 (no staining), 1+
(<15% cells, weak), 2+ (15-50% cells, moderate), 3+
(>50% cells, strong) by semi-quantitative reassortment.
CK20 cytoplasmic stain was also semiquantitatively eval-
uated: 0 (no staining), 1+ (patchy, weak), 2+ (<50% cells,
moderate), 3+ (>50% cells, strong). CK20(+) cells were
additionally described by location: Upper 1/3 urothelium
including umbrella cells, 2/3 urothelium sparing basal
layer and full-thickness staining including the basal layer.
Results
35 out of 38 (92%) benign/reactive cases were either
CK20(-) or showed CK20 positivity only in the upper 1/3
urothelium including umbrella cells and the majority, 21
out of 35 (60%), of these cases were p53(-). The remain-
ing 3 out 38 (8%) cases showed variable CK20 staining
wheras 14 out of 35 (40%) showed weak (1+) p53 posi-
tivity (Figure 1).
Among dysplastic cases, 6 out of 10 cases (60%) exhibited
CK20 positivity in 2/3 of the urothelium sparing the basal
layer while 3 cases (30%) showed full-thickness CK20
positivity, only 1 of which was accompanied by 3+ p53
positivity and 1 out 10 dysplastic (10%) cases was
CK20(+) only in 1/3 superficial urothelium (Figure 2).
8 of 9 (89%) CIS cases showed focal or diffuse full-thick-
ness CK20 positivity and 5 out of those 8 (62%) were 3+
p53(+). 1 of the CIS cases (11%) showed CK20 positivity
only in the upper 1/3 urothelium accompanied by strong
3+ p53 positivity involving the basal layer (Figure 3).
Among invasive carcinoma cases, 5 of 7 (71%) were full-
thickness CK20 positive, 2 of those cases (40%) showed
3+ p53 positivity whereas other 2 cases (40%) showed 2+
p53 positivity. The remaining 2 out of 7 (29%) cases
showed CK20 positivity other than full thickness whereas
3 out of 7 (43%) cases were p53(-) or showed weak p53
positivity. In dually positive cases, CK20 and p53 occu-
pied the full-thickness urothelium, including the basal
layer (Figure 4).Diagnostic Pathology 2009, 4:35 http://www.diagnosticpathology.org/content/4/1/35
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The distribution of location of CK20 and presence of p53
staining according to diagnosis groups are given on
Figure 5.
Discussion
The problem of distinction between reactive and dysplas-
tic atypical changes in the urothelium has not been
resolved, even after 2004 WHO/ISUP classifications [1,3].
Much inter and intraobserver disagreement constitute a
dilemma due to lack of definite morphological criteria to
diagnose CIS, dysplasia and reactive atypia.
CIS is a high-grade intraurothelial neoplasm. Patients
with CIS are at significant risk for the development of
invasive urothelial carcinoma, cancer recurrence, progres-
sion, and even death from bladder cancer [3-5,13,14].
Therefore the recognition of CIS in bladder biopsy speci-
mens is of great importance because it not only has
important prognostic implications but may also alter sub-
sequent therapy. The histopathology of urothelial CIS
may overlap with RUA resulting in diagnostic difficulty
when interpreting bladder biopsies [9]. The difficulty and
importance of distinguishing CIS from benign atypias
should not be underrated as malpractice cases involving
the failure to recognize CIS are growing in number [15].
Dysplastic intraepithelial lesions are another problematic
area that requires distinction from CIS and which pathol-
ogists frequently feel uncomfortable evaluating on the
basis of histological criteria alone.
As the distinction is therapeutically and prognostically
critical, objective ancillary markers to help in the histo-
logic differentiation between CIS and dysplasia and reac-
tive atypia are necessary. Importance of special and
Reactive urothelium (A and B) (hematoxylin eosin, original magnifications × 40 (A), × 200 (B)) Figure 1
Reactive urothelium (A and B) (hematoxylin eosin, original magnifications × 40 (A), × 200 (B)). Cytoplasmic 
immunoreactivity in reactive urothelium to CK20 in 1/3 urothelium including umbrella cells (original magnifications × 40 (C), × 
200 (D), × 400 (E)).Diagnostic Pathology 2009, 4:35 http://www.diagnosticpathology.org/content/4/1/35
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immunohistochemical stains for correct diagnosis and
accurate subclassification of controversial cases in other
lesions of urinary tract are also emphasized recently by Jin
et al [16] and Pradhan et al [17]. Previous studies have
demonstrated the diagnostic utility of separate p53 and
CK20 immunohistochemistry (IHC) in assessing neopla-
sia in bladder biopsies [11]. These markers are known to
be easy to manage and interpret. Distinctive immunoreac-
tivity patterns with antibodies against p53 and CK20 were
identified for reactive atypia and CIS [9]. Abnormal CK20
expression in urothelial cells accompanied by overexpres-
sion of p53 are considered indicators of dysplastic change
in urothelial mucosa and immunostaining with p53 and
CK20 may help accurately diagnose CIS [11,18].
To our knowledge, no previous study in the literature has
used DIHC of p53+CK20 in distinction of non-neoplastic
and neoplastic bladder lesions. In this study, we investi-
gated the utility and advantages of p53+CK20 DIHC as a
tool for detecting synchronous expression of both mark-
ers in bladder biopsies and for objectively distinguishing
the cases with CIS and dysplastic urothelial changes from
reactive nonneoplastic atypia.
The nuclear overexpression of p53 by immunohistochem-
istry has been shown to be representative of p53 tumor
suppressor gene mutation which is a common event in
neoplastic urothelium [19-26]. p53 is considered to be
nonexpressed in the nonneoplastic urothelium and over-
expression of the p53 gene product has been reported as a
marker of progression in urothelial carcinoma [24,25,27-
29]. Mutations of the p53 gene and immunohistochemi-
cal positivity for the p53 protein have been found in 40%
to 60% of urothelial carcinomas in studies of Olumi, Sid-
Dysplastic urothelium (A and C) (hematoxylin eosin, original magnifications × 200) Figure 2
Dysplastic urothelium (A and C) (hematoxylin eosin, original magnifications × 200). Cytoplasmic immunoreactivity 
in dysplastic urothelium to CK20 in 2/3 of the urothelium sparing the basal layer and nuclear 2+ immunoreactivity to p53 (orig-
inal magnification × 200 (B)). Cytoplasmic full-thickness immunoreactivity in dysplastic urothelium to CK20 (original magnifica-
tion × 100 (D)).Diagnostic Pathology 2009, 4:35 http://www.diagnosticpathology.org/content/4/1/35
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ransky and Wright et al. [21,28,30]. In nonneoplastic and
reactive urothelium, expression of p53 has been described
as varying from negative to weak and patchy, predomi-
nantly in basal and parabasal intermediate cells [9,11,31].
In parallel to these results, 60% (21/35) of the benign/
reactive group cases of our study were found to be p53(-).
In contrast, p53 was considered positive by Mallofre in
80% of the CIS cases, with 70% of those cases showing
positivity in 50% of the cells [11]. Similarly, McKenney
found that p53 was positive in 57% of the CIS cases, with
all of the cases exhibiting positivity in more than 50% of
malignant cells [9]. In our study, 10% (1/10) of the dys-
plasia, 67% (6/9) of CIS and 29% (2/7) of invasive carci-
noma cases showed strong diffuse p53 positivity whereas
another 29% (2/7) of invasive carcinoma cases exhibited
moderate p53 positivity.
If found in the cytoplasm of cells different than superficial
umbrella cells and occasional intermediate cells, CK20 is
considered abnormally expressed as a marker of abnormal
urothelial differentiation [31,32]. Urothelial de-differen-
tiation, as with neoplastic change, is accompanied by
expression of CK20 in all cell layers as shown by Harnden
et al. [8,32]. This change in the extent of expression makes
CK20 a useful and reliable marker of the neoplastic
change of urothelial cells [8,32-36]. Immunostaining for
CK20 is therefore an important addition to morphology
in the diagnosis of neoplasia, especially, in the differenti-
ation from reactive states where diagnostic difficulties are
greatest [8,37]. Cases of atypia and dysplasia that display
abnormal CK20 staining should raise the possibility of
CIS and be followed up appropriately. In the studies of
Mckenney, Mallofre and Kunju et al it has been reported
that in nonneoplastic epithelium as well as the reactive
CIS (carcinoma in situ) in urothelium (A) (hematoxylin eosin, original magnification × 400) Figure 3
CIS (carcinoma in situ) in urothelium (A) (hematoxylin eosin, original magnification × 400). Cytoplasmic full-
thickness immunoreactivity to CK20 and nuclear 3+ immunoreactivity to p53 (B and C) (original magnification × 40 (B), × 400 
(C)).Diagnostic Pathology 2009, 4:35 http://www.diagnosticpathology.org/content/4/1/35
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urothelium CK20 showed patchy cytoplasmic immunore-
activity in only the superficial umbrella cell layer
[9,11,37]. In favor of those studies, in our study, we found
that 92% (35/38) of benign/reactive cases were either
CK20(-) or showed CK20 positivity only in the upper 1/3
urothelium. While confined to superficial umbrella cells
in normal urothelium, CK20 has been reported to show
diffuse full thickness staining in 72-89% of cases of CIS
and has also been reported to be expressed in 22-58% of
invasive urothelial carcinomas [7,9,11,37-39]. However,
CK20 immunoexpression was found to be nondiscrimi-
natory in 11-28% of CIS cases due to lack of CK20 expres-
sion [7,9,11,37]. In this study, abnormal expression of CK
20 was found in 90% (9/10) of dysplasia, 89% (8/9) of
CIS and 71% (5/7) of IC cases whereas the rest of the cases
lacked abnormal CK20 expression.
Conclusion
According to our results, we can conclude that our pro-
posed immunohistochemical panel composed of p53 and
CK20 for studying dysplastic urothelial changes is ade-
quate and useful for confirming the presence of dysplastic
changes in the urothelium and can be of aid in better
defining the histological criteria of urothelial dysplasia.
Furthermore, our studies have demonstrated that
p53+CK20 cocktail (if commercially available) may be a
useful diagnostic marker in the assessment of bladder
biopsies. Two markers, in our opinion, could be used in
routine practice, together with careful clinical and mor-
phologic correlation. p53+CK20 DIHC can be considered
as a useful innovation in differentiating non-neoplastic
vs. neoplastic lesions in bladder biopsies enhancing the
credibility of the diagnosis and reducing the number of
Invasive carcinoma (A) (hematoxylin eosin, original magnification × 200) Figure 4
Invasive carcinoma (A) (hematoxylin eosin, original magnification × 200). Cytoplasmic full-thickness immunoreactiv-
ity to CK20 and nuclear 3+ immunoreactivity to p53 (B and C) (original magnification × 100 (B), × 400 (C)).Diagnostic Pathology 2009, 4:35 http://www.diagnosticpathology.org/content/4/1/35
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inconclusive pathology reports of atypia of unknown sig-
nificance consequently minimizing the need for rebiopsy
as the dual staining not only allows for histologic correla-
tion but also diminishes the risk of losing the area of inter-
est in limited biopsy specimens in recut sections.
Abbreviations
DIHC: Double immunohistochemistry; CIS: Carcinoma
in situ; IC: invasive carcinoma; WHO/ISUP: World health
organization/international society of urological pathol-
ogy; RUA: Reactive urothelial atypia; AUS: Atypia of
unknown significance; UD: Urothelial dysplasia; IHC:
Immunohistochemistry.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
IZY collected the background references, wrote the discus-
sion of the results, created the sequence of alignment and
drafted the manuscript. RR obtained the diagnostic mate-
rial from the archive of the pathology department, carried
out the immunohistochemical tests and pathological
examination, took the photomicrographs and displayed
the results of the study. HBA contributed to the prepara-
tion of the manuscript. SB, RD and AVP participated in the
design and coordination of the study and gave and
reviewed the final histopathological diagnosis. AVP
revised the manuscript. All authors read and approved the
final manuscript.
References
1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA: World Health Organization
Classification of Tumours: Pathology and Genetics of Tumours of the Uri-
nary System and Male Genital Organs Lyon: IARC Press; 2004. 
2. American Cancer Society: Cancer Facts & Figures 2008 Atlanta:Amer-
ican Cancer Society; 2008. 
3. Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health
Organization/International Society of Urological Pathology
consensus classification of urothelial (transitional cell) neo-
plasms of the urinary bladder. Bladder Consensus Confer-
ence Committee.  Am J Surg Pathol 1998, 22:1435-48.
4. Cheng L, Cheville JC, Neumann RM, Bostwick DG: Natural history
of urothelial dysplasia of the bladder.  Am J Surg Pathol 1999,
23:443-7.
5. Cheng L, Cheville JC, Neumann RM, Leibovich BC, Egan KS, Spotts
BE, Bostwick DG: Survival of patients with carcinoma in situ of
the urinary bladder.  Cancer 1999, 85:2469-74.
6. McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB: Morphologic
expressions of urothelial carcinoma in situ: a detailed evalu-
ation of its histologic patterns with emphasis on carcinoma
in situ with microinvasion.  Am J Surg Pathol 2001, 25:356-62.
7. Yin H, He Q, Li T, Leong AS: Cytokeratin 20 and Ki-67 to distin-
guish carcinoma in situ from flat non-neoplastic urothelium.
Appl Immunohistochem Mol Morphol 2006, 14(3):260-5.
The distribution of location of CK20 staining in the urothelium and presence of p53 staining (0 and 1+ staining = p53 -, 2+ and  3+ staining = p53 +) according to diagnosis (CIS: carcinoma in situ and IC:invasive carcinoma) groups Figure 5
The distribution of location of CK20 staining in the urothelium and presence of p53 staining (0 and 1+ staining 
= p53 -, 2+ and 3+ staining = p53 +) according to diagnosis (CIS: carcinoma in situ and IC:invasive carcinoma) 
groups.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Diagnostic Pathology 2009, 4:35 http://www.diagnosticpathology.org/content/4/1/35
Page 8 of 8
(page number not for citation purposes)
8. Harnden P, Eardley I, Joyce AD, Southgate J: Cytokeratin 20 as an
objective marker of urothelial dysplasia.  Br J Urol 1996,
78:870-75.
9. McKenney JK, Desai S, Cohen C, Amin MB: Discriminatory immu-
nohistochemical staining of urothelial carcinoma in situ and
non-neoplastic urothelium: an analysis of cytokeratin 20,
p53, and CD44 antigens.  Am J Surg Pathol 2001, 25:1074-8.
10. Sun W, Zhang PL, Herrera GA: p53 protein and Ki-67 overex-
pression in urothelial dysplasia of bladder.  Appl Immunohisto-
chem Mol Morphol 2002, 10:327-31.
11. Mallofre C, Castillo M, Morente V, Sole M: Immunohistochemical
expression of CK20, p53, and Ki-67 as objective markers of
urothelial dysplasia.  Mod Pathol 2003, 16:187-91.
12. Retz M, Lehmann J, Amann E, Wullich B, Roder C, Stockle M: Mucin
7 and cytokeratin 20 as new diagnostic urinary markers for
bladder tumor.  J Urol 2003, 169:86-9.
13. Bostwick DG: Natural history of early bladder cancer.  J Cell Bio-
chem 1992, 161(suppl):31-8.
14. Farrow GM, Utz DC, Rife CC, Greene LF: Clinical observations
on sixty-nine cases of in situ carcinoma of the urinary blad-
der.  Cancer Res 1977, 37:2794-8.
15. Troxel DB: Suits & Briefs.  CAP Today 2000, 14:88.
16. Jin B, Zaidi SY, Hollowell M, Hollowell C, Saleh H: A unique case of
urinary bladder simple melanosis: a case report and review
of the literature.  Diagn Pathol 2009, 4:24.
17. Pradhan D, Kakkar N, Bal A, Singh SK, Joshi K: Sub-typing of renal
cell tumours; contribution of ancillary techniques.  Diagn
Pathol 2009, 4:21.
18. Nese N, Gupta R, Bui MH, Amin MB: Carcinoma in situ of the uri-
nary bladder: review of clinicopathologic characteristics with
an emphasis on aspects related to molecular diagnostic tech-
niques and prognosis.  J Natl Compr Canc Netw 2009, 7(1):48-57.
19. Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression
of mutant forms of p53 oncogene in primary lung cancer.
Lancet 1990, 335:675.
20. Lohmann D, Ruhri C, Schmitt M, Graeff H, Höfler H: Accumulation
of p53 protein as an indicator for p53 gene mutation in
breast cancer: occurrence of false-positives and false nega-
tives.  Diagn Mol Pathol 1993, 2:36.
21. Sidransky D, von Eschenbach A, Tsai YC, Jones P, Summerhayes I,
Marshall F, Paul M, Green P, Hamilton SR, Frost P, et al.: Identifica-
tion of p53 gene mutations in bladder cancers and urine sam-
ples.  Science 1991, 25:705-709.
22. Krause FS, Feil G, Bichler KH: Immunohistochemical examina-
tions (Ki67, p53, nm23) and DNA cytophotometry in bladder
cancer.  Anticancer Res 2000, 20:5023-5028.
23. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK: Cyclin
D1 expression in transitional cell carcinoma of the bladder:
correlation with p53, waf1, pRb and Ki67.  Br J Cancer 2001,
84:270-275.
24. Cina SJ, Lancaster-Weiss KJ, Lecksell K, Epstein JI: Correlation of
Ki67 and p53 with the new World Health Organization/
International Society of Urological Pathology classification
system for urothelial neoplasia.  Arch Pathol Lab Med 2001,
125:646-651.
25. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T,
Terada M: Frequent association of p53 gene mutation in inva-
sive bladder cancer.  Cancer Res 1992, 52:1393-1398.
26. Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Navone R: Bio-
logical differences between noninvasive papillary urothelial
neoplasms of low malignant potential and low-grade (grade
1) papillary carcinomas of the bladder.  Am J Surg Pathol 2001,
25:1528-1533.
27. Cordon-Cardo C, Reuter V: Alterations of tumor suppressor
genes in bladder cancer.  Semin Diagn Pathol 1997, 14:123-32.
28. Wright C, Mellon K, Johnston P: Expression of mutant p53, c-
erb-B2 and epidermal growth factor receptor in transitional
cell carcinoma of the human urinary bladder.  Br J Cancer 1991,
63:967-70.
29. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang ZF, Shein-
feld J, Fair WR, Herr HW, Reuter VE: Association of p53 nuclear
overexpression and tumor progression in carcinoma in situ
of the bladder.  J Urol 1994, 152:388-92.
30. Olumi AF, Tsai YC, Nichols PW, Skinner DG, Cain DR, Bender LI,
Jones PA: Allelic loss of chromosome 17p distinguishes high
grade from low grade transitional cell carcinomas of the
bladder.  Cancer Res 1990, 50:7081-7083.
31. Yin H, Leong AS: Histologic grading of noninvasive papillary
urothelial tumors: validation of the 1998 WHO/ISUP system
by immunophenotyping and follow-up.  Am J Clin Pathol 2004,
121(5):679-87.
32. Harnden P, Mahmood N, Southgate J: Expression of cytokeratin
20 redefines urothelial papillomas of the bladder.  Lancet 1999,
353:974-977.
33. Chu P, Wu E, Weiss LM: Cytokeratin 7 and cytokeratin 20
expression in epithelial neoplasms: a survey of 435 cases.
Mod Pathol 2000, 13(9):962-72.
34. Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, Zav-
ala-Pompa A, Cohen C, Young RH, Amin MB: Relation of cytoker-
atin 20 and CD44 protein expression with WHO/ISUP grade
pTa and pT1 papillary urothelial neoplasia.  Mod Pathol 2000,
13(12):1315-23.
35. Klein A, Zemer R, Buchumensky V, Klaper R, Nisserkon I: Expres-
sion of cytokeratin 20 in urinary cytology of patients with
bladder carcinoma.  Cancer 1998, 82:349-54.
36. Alsheik A, Mohamedali Z, Jones E, Masterson J, Gilks CB: Compari-
son of the WHO/ISUP classification and cytokeratin expres-
sion in predicting the behaviour of low-grade papillary
urothelial tumors.  Mod Pathol 2001, 14(4):267-72.
37. Kunju LP, Lee CT, Montie J, Shah RB: Utility of cytokeratin 20 and
Ki-67 as markers of urothelial dysplasia.  Pathol Int 2005,
55(5):248-54.
38. Genega EM, Hutchinson B, Reuter VE, Gaudin PB: Immunopheno-
type of high-grade prostatic adenocarcinoma and urothelial
carcinoma.  Mod Pathol 2000, 13:1186-91.
39. Parker DC, Folpe AL, Bell J, Oliva E, Young RH, Cohen C, Amin MB:
Potential utility of uroplakin III, thrombomodulin, high
molecular weight cytokeratin, and cytokeratin 20 in nonin-
vasive, invasive, and metastatic urothelial (transitional cell)
carcinomas.  Am J Surg Pathol 2003, 27:1-10.